Trump negotiating deal with Ozempic maker to sell some weight-loss drugs for $149

Core Insights - Novo Nordisk and Eli Lilly are set to gain Medicare and Medicaid coverage for their leading weight-loss drugs [1] Company Summary - Novo Nordisk will benefit from the expanded coverage of its weight-loss drugs under Medicare and Medicaid [1] - Eli Lilly is also positioned to gain from the same coverage expansion for its weight-loss medications [1] Industry Summary - The inclusion of weight-loss drugs in Medicare and Medicaid signifies a potential shift in the healthcare landscape, impacting the pharmaceutical industry [1] - This development may lead to increased market access and sales growth for companies like Novo Nordisk and Eli Lilly in the weight-loss drug segment [1]